MA
VRTX icon

Mutual Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Mutual Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.76M Buy
3,552
+43
+1% +$19.1K 0.03% 452
2026
Q1 		$1.57M Buy
3,509
+33
+0.9% +$15.4K 0.03% 449
2025
Q4 		$1.58M Sell
3,476
-346
-9% -$149K 0.03% 422
2025
Q3 		$1.62M Buy
3,822
+547
+17% +$229K 0.04% 422
2025
Q2 		$1.54M Buy
3,275
+191
+6% +$88K 0.04% 378
2025
Q1 		$1.52M Sell
3,084
-139
-4% -$64.8K 0.04% 347
2024
Q4 		$1.34M Sell
3,223
-487
-13% -$226K 0.04% 390
2024
Q3 		$1.75M Buy
3,710
+21
+0.6% +$10.1K 0.05% 306
2024
Q2 		$1.84M Buy
3,689
+433
+13% +$188K 0.06% 292
2024
Q1 		$1.36M Sell
3,256
-64
-2% -$27.1K 0.04% 379
2023
Q4 		$1.35M Buy
3,320
+271
+9% +$100K 0.05% 369
2023
Q3 		$1.06M Sell
3,049
-80
-3% -$28K 0.04% 407
2023
Q2 		$1.1M Buy
3,129
+171
+6% +$57.6K 0.04% 410
2023
Q1 		$932K Sell
2,958
-88
-3% -$26.4K 0.04% 441
2022
Q4 		$880K Sell
3,046
-27
-0.9% -$8.23K 0.04% 439
2022
Q3 		$890K Sell
3,073
-354
-10% -$102K 0.05% 400
2022
Q2 		$966K Sell
3,427
-4
-0.1% -$1.07K 0.06% 345
2022
Q1 		$895K Buy
3,431
+48
+1% +$11.4K 0.05% 410
2021
Q4 		$743K Buy
3,383
+147
+5% +$28.6K 0.04% 477
2021
Q3 		$587K Buy
3,236
+2
+0.1% +$390 0.03% 500
2021
Q2 		$652K Buy
3,234
+2,300
+246% +$481K 0.04% 459
2021
Q1 		$201K Buy
+934
New +$205K 0.01% 736
2020
Q3 		– Sell
-2,208
Closed -$641K – 711
2020
Q2 		$641K Buy
+2,208
New +$599K 0.06% 317
2020
Q1 		– Sell
-1,105
Closed -$242K – 644
2019
Q4 		$242K Buy
+1,105
New +$224K 0.03% 520

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Mutual Advisors's VRTX Position: Q2 2026 in Review

Mutual Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 1.2% in Q2 2026, buying an estimated $19.1K and bringing the position to 3,552 shares worth $1.76M. The position accounts for 0.03% of the portfolio, ranked #452.

Mutual Advisors first reported a position in VRTX in Q4 2019 and has held it in 24 quarters since. The position peaked at $1.84M in Q2 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Mutual Advisors held 3,552 shares of Vertex Pharmaceuticals worth $1.76M as of Q2 2026.
  • Mutual Advisors bought 43 Vertex Pharmaceuticals shares in Q2 2026, an estimated $19.1K.
  • Vertex Pharmaceuticals made up 0.03% of Mutual Advisors's portfolio in Q2 2026, its #452 holding.
  • Mutual Advisors first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 24 quarters since.
  • Mutual Advisors's Vertex Pharmaceuticals position peaked at $1.84M in Q2 2024.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Mutual Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.